Lineage Cell Valuation
| BTX Stock | ILS 447.30 14.00 3.23% |
At this time, the firm appears to be overvalued. Lineage Cell Therapeutics secures a last-minute Real Value of S383.06 per share. The latest price of the firm is S447.3. Our model forecasts the value of Lineage Cell Therapeutics from analyzing the firm fundamentals such as Price To Book of 1.14 X, ebitda of (37.2 M), and Revenue of 4.99 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend taking in undervalued stocks and trading overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Lineage Cell's price fluctuation is very steady at this time. Calculation of the real value of Lineage Cell Therapeutics is based on 3 months time horizon. Increasing Lineage Cell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Lineage Cell Therapeutics is useful when determining the fair value of the Lineage stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Lineage Cell. Since Lineage Cell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lineage Stock. However, Lineage Cell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 447.3 | Real 383.06 | Hype 447.3 | Naive 385.22 |
The real value of Lineage Stock, also known as its intrinsic value, is the underlying worth of Lineage Cell Therapeutics Company, which is reflected in its stock price. It is based on Lineage Cell's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Lineage Cell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lineage Cell's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lineage Cell Therapeutics helps investors to forecast how Lineage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lineage Cell more accurately as focusing exclusively on Lineage Cell's fundamentals will not take into account other important factors: Lineage Cell Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.Lineage Cell Therapeutics is number one stock in price to book category among related companies. It is number one stock in price to sales category among related companies fabricating about 34.33 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lineage Cell by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lineage Cell's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lineage Cell's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lineage Cell's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lineage Cell and how it compares across the competition.
About Lineage Cell Valuation
The stock valuation mechanism determines the current worth of Lineage Cell Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Lineage Cell Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lineage Cell Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Lineage Cell's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Lineage Cell's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lineage Cell. We calculate exposure to Lineage Cell's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Lineage Cell's related companies.BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.
8 Steps to conduct Lineage Cell's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Lineage Cell's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Lineage Cell's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Lineage Cell's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Lineage Cell's revenue streams: Identify Lineage Cell's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Lineage Cell's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Lineage Cell's growth potential: Evaluate Lineage Cell's management, business model, and growth potential.
- Determine Lineage Cell's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Lineage Cell's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |